Recent neuroscience studies have been investigating how the stimulation of some nerves, particularly the vagus nerve, using ...

While schizophrenia treatments primarily target the dopamine neurotransmitter system in the brain, Cobenfy goes after a different one, the cholinergic system, through muscarinic receptors.

Genomic Press Interview reveals Hebrew University Professor Soreq's groundbreaking research on acetylcholine and small RNA regulators in brain-body ... on the cholinergic system and small RNA ...

Phosphatidylserine provides brain plasticity, the ability to concentrate, and think logically Ashwagandha helps reduce the formation of amyloid plaques and cope with stress Bacopa aids in restoring ...

The new mechanism of action targets cholinergic receptors instead of the standard dopamine ... medicines approved to treat schizophrenia have relied on the same primary pathways in the brain. By ...

For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building ...